Comparative Pharmacology
Head-to-head clinical analysis: ATOVAQUONE versus BENZNIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATOVAQUONE versus BENZNIDAZOLE.
ATOVAQUONE vs BENZNIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain complex III (cytochrome bc1 complex) in parasites, thereby disrupting pyrimidine synthesis and energy metabolism.
Benznidazole is a nitroimidazole derivative that exerts trypanocidal activity against Trypanosoma cruzi. Its mechanism involves the reduction of the nitro group by a nitroreductase enzyme in the parasite, leading to the generation of toxic metabolites that damage parasite DNA and other cellular components.
750 mg oral suspension twice daily for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia; 1500 mg oral suspension once daily for prophylaxis.
5-7 mg/kg/day orally divided into two daily doses for 60 days. Maximum daily dose: 300 mg.
None Documented
None Documented
Clinical Note
moderateAtovaquone + Indinavir
"The serum concentration of Indinavir can be decreased when it is combined with Atovaquone."
Clinical Note
moderateBenznidazole + Leflunomide
"The risk or severity of adverse effects can be increased when Benznidazole is combined with Leflunomide."
Clinical Note
moderateAtovaquone + Artemether
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
Clinical Note
moderateAtovaquone + Lumefantrine
Terminal elimination half-life is approximately 2-3 days (67 hours) in adults, prolonged in renal or hepatic impairment.
Terminal elimination half-life is approximately 12 hours; may be prolonged in hepatic impairment.
Primarily fecal (>94%) as unchanged drug; renal excretion is minimal (<1%).
Primarily renal excretion of metabolites; <5% unchanged drug. Approximately 20% in feces.
Category A/B
Category C
Antiprotozoal
Antiprotozoal
"The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."